PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A pilot study using 400 mg of zerumbone twice daily showed significant improvements in quality of life regarding activity and social and emotional functioning [PMID:38199583].
In vitro studies demonstrate dose-dependent growth inhibition and induction of apoptosis in RD and RH30 cells, with downregulation of the hedgehog pathway [PMID:35931788].
Zerumbone attenuated LPS-induced acute lung injury by suppressing the NLRP3/Caspase-1/GSDMD signaling pathway [PMID:41053917].
Ethyl acetate extract from Z. zerumbet rhizomes demonstrated anti-pyretic activities in yeast-induced fever [PMID:38558027].
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 38199583 (2024) — Bitter ginger (Zingiber zerumbet) for patients with solid tumors with no treatment options: A pilot clinical study. · Complementary therapies in medicine
- 2.PMID: 37480373 (2023) — Zingiber zerumbet (L.) Roscoe ex Sm.: biotechnological advancements and perspectives. · Applied microbiology and biotechnology
- 3.PMID: 38035621 (2024) — Zingiber zerumbet: A Scoping Review of its Medicinal Properties. · Planta medica
- 4.PMID: 35335369 (2022) — Synthesis of Silver Nanoparticles from Extracts of Wild Ginger (Zingiber zerumbet) with Antibacterial Activity against Selective Multidrug Resistant Oral Bacteria. · Molecules (Basel, Switzerland)
- 5.PMID: 22533311 (2013)